Board Member
Beam Therapeutics Inc. (BEAM)Chairman
Kyverna Therapeutics, Inc. (KYTX)Board Member
Kyverna Therapeutics, Inc. (KYTX)Equibles does not estimate personal net worth.
Get an email with a short summary when Gilead Sciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get GILD alertsChristi Shaw is recorded as CEO at Gilead Sciences, Inc. (GILD), Board Member at Beam Therapeutics Inc. (BEAM), Chairman at Kyverna Therapeutics, Inc. (KYTX) since January 12, 2026 and Board Member at Kyverna Therapeutics, Inc. (KYTX) since January 1, 2024. The newest filing on record that lists Christi Shaw as Board Member at Beam Therapeutics Inc. (BEAM) is dated April 17, 2026. The newest filing on record that lists Christi Shaw as Board Member at Kyverna Therapeutics, Inc. (KYTX) is dated April 13, 2026. Christi Shaw was last confirmed as Board Member at Avantor, Inc. (AVTR) in a filing dated March 31, 2023. Kyverna Therapeutics, Inc. reported in an 8-K filed January 12, 2026 that Christi Shaw was appointed Executive Chairperson of the Board, effective January 12, 2026. Kyverna Therapeutics, Inc. reported in an 8-K filed September 16, 2024 that Christi Shaw was appointed Class II director, effective September 14, 2024. Beam Therapeutics Inc. reported in an 8-K filed December 14, 2023 that Christi Shaw was appointed member of the Board, effective December 13, 2023. Christi Shaw has spoken on 7 earnings calls across 1 company, most recently for Gilead Sciences, Inc. on February 2, 2023. Gilead Sciences, Inc. is classified in the Drug Manufacturers - General industry within the Healthcare sector. Beam Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Gilead Sciences, Inc. includes Daniel P. O’Day (CEO), Robin L. Washington (CFO), Diane E. Wilfong (Chief Accounting Officer) and 7 others.
“On January 8, 2026, the Board appointed Christi Shaw, a current member of the Board, as the Company's Executive Chairperson of the Board, effective January 12, 2026 (the "Effective Date").”
“On September 14, 2024, the Board appointed Christi Shaw as a Class II director of the Company, effective September 14, 2024.”
“We think it's very important because first of all, the number of patients is still very similar at 450, but the process by which patients get approved, obviously should be much smoother and really give patients access much more quickly.”
“I'll start with the second piece, reimbursement. Our reimbursement is really good. We have 98% access, and that's Medicaid, Medicare, and commercial. Even with the second-line launch, in less than one quarter, we already had 94% paid for across the three groups.”
“First, prior to the approval, the NCCN guidelines changed to classify Yescarta for LBCL second-line treatment as category 1, which is significant because physicians and providers refer to this to determine standard care.”
“We are very excited about not only the second line, which is crucial for helping the most patients, but also the ongoing success of the third line along with the five-year data presented at ASH.”
“Yes, we're very excited about our submission at the end of September for second-line and expect to hear back on the status from the FDA first half of next year.”
2026-01-12–present
2024-01-01–present
Last confirmed April 13, 2026
Start not stated–present
Last confirmed April 17, 2026
Start not stated–2023-03-31
Last confirmed by a filing; no departure on record
Drug Manufacturers - General · Healthcare
CEO
Biotechnology · Healthcare
Chairman, Board Member
2024-01-01–present
